milrinone has been researched along with Cardiovascular Stroke in 37 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to compare the hemodynamic and clinical effects of milrinone, a vasodilating and positive inotropic agent, with those of dobutamine in patients with congestive heart failure (CHF) following acute myocardial infarction (AMI)." | 9.08 | Comparative efficacy of short-term intravenous infusions of milrinone and dobutamine in acute congestive heart failure following acute myocardial infarction. Milrinone-Dobutamine Study Group. ( Berk, MR; DeMaria, AN; DeWood, MA; Karlsberg, RP; Lasher, KP, 1996) |
| "The authors examined whether milrinone and levosimendan could exert cardiac postconditioning effects in rats under normoglycemia and hyperglycemia, and whether the effects could be mediated by mitochondrial permeability transition pore (mPTP)." | 7.78 | Hyperglycemia raises the threshold of levosimendan- but not milrinone-induced postconditioning in rat hearts. ( Cho, S; Hara, T; Higashijima, U; Maekawa, T; Matsumoto, S; Sumikawa, K; Tosaka, S, 2012) |
| "This study compared the effects of simendan, a calcium sensitizer, with those of milrinone and enalapril on survival of rats with healed myocardial infarction." | 7.71 | Improved survival with simendan after experimental myocardial infarction in rats. ( Haikala, H; Kaheinen, P; Levijoki, J; Pollesello, P, 2001) |
| "Chronic milrinone therapy after acute myocardial infarction improves cardiac hemodynamic indexes and attenuates progressive left ventricular dilation." | 7.68 | Effects of milrinone on left ventricular remodeling after acute myocardial infarction. ( Brown, EJ; Halpern, J; Jain, P; Langenback, EG; Lillis, O; Mannisi, JA; Raeder, E, 1991) |
| "The effects of milrinone and pimobendan upon the initiation of programmed ventricular stimulation-induced ventricular tachycardia (VT) and the incidence of lethal ischemic ventricular arrhythmias were assessed in conscious dogs with recent anterior myocardial infarctions." | 7.67 | Effects of the positive inotropic agents milrinone and pimobendan on the development of lethal ischemic arrhythmias in conscious dogs with recent myocardial infarction. ( Driscoll, EM; Frye, JW; Kitzen, JM; Lucchesi, BR; Lynch, JJ; Uprichard, AC, 1989) |
| "The long-term survival of rats with healed myocardial infarction and congestive heart failure treated with milrinone, enalapril and the combination of milrinone plus enalapril, was documented." | 7.67 | Beneficial effects of milrinone and enalapril on long-term survival of rats with healed myocardial infarction. ( Emmert, SE; Heyse, JF; Ludden, CT; Stabilito, II; Sweet, CS, 1988) |
| "The present study was designed to evaluate the regional vascular profile of milrinone in the setting of experimental heart failure." | 7.67 | [Central and regional vascular hemodynamics of milrinone in experimental heart failure: comparison with captopril and dobutamine]. ( Drexler, H; Faude, F; Freudenberg, N; Just, H; Winterer, H; Wollschläger, H, 1987) |
| "The combination therapy with M + E produces a minimal change in hemodynamics and appears safe as an adjunctive therapy to PCI in AMI patients." | 6.79 | Safety of combination therapy with milrinone and esmolol for heart protection during percutaneous coronary intervention in acute myocardial infarction. ( Chan, KH; Chan, MY; Fujise, K; Huang, MH; Lee, CH; Low, AF; Lui, CY; Nguyen, V; Poh, KK; Sia, W; Tan, HC; Tang, LQ; Tay, EL; Xu, X, 2014) |
| "The milrinone plasma level was significantly greater in group III than in the other groups (group I, 0 ng/mL; group II, 1." | 5.40 | Sustained release of milrinone delivered via microparticles in a rodent model of myocardial infarction. ( Al Kindi, H; Nepotchatykh, O; Paul, A; Prakash, S; Schwertani, A; Shum-Tim, D; You, Z, 2014) |
| "Myocardial ischemia was induced by left coronary artery branch occlusion and quantitated from epicardial NADH-fluorescence photography." | 5.29 | Effect of amrinone and milrinone on myocardial ischemia extent and infarct size in isolated rabbit hearts. ( Blazincic, B; Klaus, W; Rump, AF, 1993) |
| "Milrinone is a phosphodiesterase inhibitor which combines vasodilating effects with inotropic effects." | 5.28 | Beneficial hemodynamic effects of two weeks' milrinone treatment in conscious rats with heart failure. ( Debets, JJ; Schoemaker, RG; Smits, JF; Struyker-Boudier, HA, 1990) |
| "Treatment with milrinone (2." | 5.28 | Beneficial hemodynamic effects of milrinone and enalapril in conscious rats with healed myocardial infarction. ( DeFelice, A; Frering, R; Harris, A; Horan, P, 1989) |
| "Serum levels of creatine phosphokinase (CPK), the MB isoenzyme of creatine kinase (CK-MB), occurrence of myocardial ischemia or infarction, and mean duration of using inotropic agents were significantly lower in the milrinone group (p < 0." | 5.14 | Effect of milrinone on short-term outcome of patients with myocardial dysfunction undergoing coronary artery bypass graft: A randomized controlled trial. ( Darehzereshki, A; Dianat, S; Eghtesadi-Araghi, P; Ghazinoor, M; Goodarzynejad, H; Jebeli, M; Mandegar, MH; Mohammadzadeh, R; Rasouli, MR, 2010) |
| "The purpose of this study was to compare the hemodynamic and clinical effects of milrinone, a vasodilating and positive inotropic agent, with those of dobutamine in patients with congestive heart failure (CHF) following acute myocardial infarction (AMI)." | 5.08 | Comparative efficacy of short-term intravenous infusions of milrinone and dobutamine in acute congestive heart failure following acute myocardial infarction. Milrinone-Dobutamine Study Group. ( Berk, MR; DeMaria, AN; DeWood, MA; Karlsberg, RP; Lasher, KP, 1996) |
| " 1) Milrinone decreased incidence of myocardial ischemia and myocardial infarction (15." | 4.93 | Effect of milrinone on cardiac functions in patients undergoing coronary artery bypass graft: a meta-analysis of randomized clinical trials. ( Cheng, X; Huang, L; Jiang, X; Wu, Q; Wu, Y; You, Z, 2016) |
| " Parenteral sympathomimetic agents, usually dobutamine, and phosphodiesterase inhibitors, usually milrinone, are used for the management of exacerbations of chronic systolic heart failure." | 4.82 | Role of nonglycosidic inotropic agents: indications, ethics, and limitations. ( Chatterjee, K; De Marco, T, 2003) |
| "The authors examined whether milrinone and levosimendan could exert cardiac postconditioning effects in rats under normoglycemia and hyperglycemia, and whether the effects could be mediated by mitochondrial permeability transition pore (mPTP)." | 3.78 | Hyperglycemia raises the threshold of levosimendan- but not milrinone-induced postconditioning in rat hearts. ( Cho, S; Hara, T; Higashijima, U; Maekawa, T; Matsumoto, S; Sumikawa, K; Tosaka, S, 2012) |
| "To evaluate: 1) the effects of dobutamine (DOB) on left ventricular function in early (48-72 h) and late (14 days) phases of a post-MI canine model, compared to ISTA, and 2) the efficacy of DOB in chronic left ventricular dysfunction (6 months post-MI) in dogs pre-treated or not with a beta-blocker, compared with ISTA and milrinone (MIL)." | 3.74 | Sympathomimetic inefficiency in restoring contractility in the acute or chronic beta-blocker-treated ischaemic heart: comparison with a new agent. ( Borsini, F; Carminati, P; Gagnol, JP; Loi, FM; Mattera, GG; Vanoli, E, 2008) |
| "This study compared the effects of simendan, a calcium sensitizer, with those of milrinone and enalapril on survival of rats with healed myocardial infarction." | 3.71 | Improved survival with simendan after experimental myocardial infarction in rats. ( Haikala, H; Kaheinen, P; Levijoki, J; Pollesello, P, 2001) |
| "Chronic milrinone therapy after acute myocardial infarction improves cardiac hemodynamic indexes and attenuates progressive left ventricular dilation." | 3.68 | Effects of milrinone on left ventricular remodeling after acute myocardial infarction. ( Brown, EJ; Halpern, J; Jain, P; Langenback, EG; Lillis, O; Mannisi, JA; Raeder, E, 1991) |
| "The effects of milrinone and pimobendan upon the initiation of programmed ventricular stimulation-induced ventricular tachycardia (VT) and the incidence of lethal ischemic ventricular arrhythmias were assessed in conscious dogs with recent anterior myocardial infarctions." | 3.67 | Effects of the positive inotropic agents milrinone and pimobendan on the development of lethal ischemic arrhythmias in conscious dogs with recent myocardial infarction. ( Driscoll, EM; Frye, JW; Kitzen, JM; Lucchesi, BR; Lynch, JJ; Uprichard, AC, 1989) |
| "The long-term survival of rats with healed myocardial infarction and congestive heart failure treated with milrinone, enalapril and the combination of milrinone plus enalapril, was documented." | 3.67 | Beneficial effects of milrinone and enalapril on long-term survival of rats with healed myocardial infarction. ( Emmert, SE; Heyse, JF; Ludden, CT; Stabilito, II; Sweet, CS, 1988) |
| "The present study was designed to evaluate the regional vascular profile of milrinone in the setting of experimental heart failure." | 3.67 | [Central and regional vascular hemodynamics of milrinone in experimental heart failure: comparison with captopril and dobutamine]. ( Drexler, H; Faude, F; Freudenberg, N; Just, H; Winterer, H; Wollschläger, H, 1987) |
| "The combination therapy with M + E produces a minimal change in hemodynamics and appears safe as an adjunctive therapy to PCI in AMI patients." | 2.79 | Safety of combination therapy with milrinone and esmolol for heart protection during percutaneous coronary intervention in acute myocardial infarction. ( Chan, KH; Chan, MY; Fujise, K; Huang, MH; Lee, CH; Low, AF; Lui, CY; Nguyen, V; Poh, KK; Sia, W; Tan, HC; Tang, LQ; Tay, EL; Xu, X, 2014) |
| "The milrinone plasma level was significantly greater in group III than in the other groups (group I, 0 ng/mL; group II, 1." | 1.40 | Sustained release of milrinone delivered via microparticles in a rodent model of myocardial infarction. ( Al Kindi, H; Nepotchatykh, O; Paul, A; Prakash, S; Schwertani, A; Shum-Tim, D; You, Z, 2014) |
| "Olprinone was also examined with an intracoronary cotreatment with a PKA inhibitor (H89), a PKC inhibitor (GF109203X), an extracellular signal-regulated kinase kinase (MEK) inhibitor (PD98059), or a p38 MAPK inhibitor (SB203580) throughout the preischemic period." | 1.31 | Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitors: the role of protein kinase A and p38 mitogen-activated protein kinase. ( Asakura, M; Asanuma, H; Fukushima, T; Hori, M; Kitakaze, M; Kuzuya, T; Liao, Y; Mori, H; Node, K; Ogai, A; Ogita, H; Papst, PJ; Sakata, Y; Sanada, S; Shinozaki, Y; Takashima, S; Terada, N; Yamada, J, 2001) |
| "Myocardial ischemia was induced by left coronary artery branch occlusion and quantitated from epicardial NADH-fluorescence photography." | 1.29 | Effect of amrinone and milrinone on myocardial ischemia extent and infarct size in isolated rabbit hearts. ( Blazincic, B; Klaus, W; Rump, AF, 1993) |
| "Milrinone is a phosphodiesterase inhibitor which combines vasodilating effects with inotropic effects." | 1.28 | Beneficial hemodynamic effects of two weeks' milrinone treatment in conscious rats with heart failure. ( Debets, JJ; Schoemaker, RG; Smits, JF; Struyker-Boudier, HA, 1990) |
| "Treatment with milrinone (2." | 1.28 | Beneficial hemodynamic effects of milrinone and enalapril in conscious rats with healed myocardial infarction. ( DeFelice, A; Frering, R; Harris, A; Horan, P, 1989) |
| "Enalaprilat was tested in a similar design with the infusion phase (70 micrograms/kg, total dose) separated by oral enalapril (Enal), 1 mg/kg/day." | 1.27 | Acute and subacute hemodynamic effects of enalaprilat, milrinone and combination therapy in rats with chronic left ventricular dysfunction. ( Emmert, SE; Stabilito, II; Sweet, CS, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (21.62) | 18.7374 |
| 1990's | 10 (27.03) | 18.2507 |
| 2000's | 6 (16.22) | 29.6817 |
| 2010's | 10 (27.03) | 24.3611 |
| 2020's | 3 (8.11) | 2.80 |
| Authors | Studies |
|---|---|
| Jung, RG | 2 |
| Di Santo, P | 2 |
| Mathew, R | 2 |
| Abdel-Razek, O | 2 |
| Parlow, S | 2 |
| Simard, T | 2 |
| Marbach, JA | 1 |
| Gillmore, T | 1 |
| Mao, B | 1 |
| Bernick, J | 1 |
| Theriault-Lauzier, P | 1 |
| Fu, A | 2 |
| Lau, L | 1 |
| Motazedian, P | 2 |
| Russo, JJ | 1 |
| Labinaz, M | 1 |
| Hibbert, B | 2 |
| Prosperi-Porta, G | 1 |
| Hutson, J | 1 |
| Malhotra, N | 1 |
| Ramirez, FD | 1 |
| Froeschl, M | 1 |
| Torregroza, C | 1 |
| Maas, K | 1 |
| Feige, K | 1 |
| Raupach, A | 2 |
| Stroethoff, M | 1 |
| Heinen, A | 2 |
| Hollmann, MW | 2 |
| Huhn, R | 2 |
| Behmenburg, F | 1 |
| Trefz, L | 1 |
| Dorsch, M | 1 |
| Ströthoff, M | 1 |
| Mathes, A | 1 |
| Berger, MM | 1 |
| Lee, TM | 1 |
| Lin, SZ | 1 |
| Chang, NC | 1 |
| Poh, KK | 1 |
| Xu, X | 1 |
| Chan, MY | 1 |
| Lee, CH | 1 |
| Tay, EL | 1 |
| Low, AF | 1 |
| Chan, KH | 1 |
| Sia, W | 1 |
| Tang, LQ | 1 |
| Tan, HC | 1 |
| Lui, CY | 1 |
| Nguyen, V | 1 |
| Fujise, K | 1 |
| Huang, MH | 1 |
| Al Kindi, H | 1 |
| Paul, A | 1 |
| You, Z | 2 |
| Nepotchatykh, O | 1 |
| Schwertani, A | 1 |
| Prakash, S | 1 |
| Shum-Tim, D | 1 |
| Tang, X | 1 |
| Liu, P | 1 |
| Li, R | 1 |
| Jing, Q | 1 |
| Lv, J | 1 |
| Liu, L | 1 |
| Liu, Y | 1 |
| Novaes, RD | 1 |
| Gonçalves, RV | 1 |
| Huang, L | 1 |
| Cheng, X | 1 |
| Wu, Q | 1 |
| Jiang, X | 1 |
| Wu, Y | 1 |
| Mattera, GG | 1 |
| Vanoli, E | 1 |
| Gagnol, JP | 1 |
| Loi, FM | 1 |
| Borsini, F | 1 |
| Carminati, P | 1 |
| Hein, M | 1 |
| Roehl, AB | 1 |
| Baumert, JH | 1 |
| Scherer, K | 1 |
| Steendijk, P | 1 |
| Rossaint, R | 1 |
| Jebeli, M | 1 |
| Ghazinoor, M | 1 |
| Mandegar, MH | 1 |
| Rasouli, MR | 1 |
| Eghtesadi-Araghi, P | 1 |
| Goodarzynejad, H | 1 |
| Mohammadzadeh, R | 1 |
| Darehzereshki, A | 1 |
| Dianat, S | 1 |
| Matsumoto, S | 1 |
| Cho, S | 1 |
| Tosaka, S | 1 |
| Higashijima, U | 1 |
| Maekawa, T | 1 |
| Hara, T | 1 |
| Sumikawa, K | 1 |
| Chatterjee, K | 1 |
| De Marco, T | 1 |
| Palmaers, T | 1 |
| Albrecht, S | 1 |
| Heuser, F | 1 |
| Leuthold, C | 1 |
| Schuettler, J | 1 |
| Schmitz, B | 1 |
| Alonso Francia, C | 1 |
| Calvo Cebollero, I | 1 |
| Diarte de Miguel, JA | 1 |
| Gomollón García, JP | 1 |
| Placer Peralta, LJ | 1 |
| Rump, AF | 1 |
| Blazincic, B | 1 |
| Klaus, W | 1 |
| Jain, P | 2 |
| Hughes, M | 1 |
| Korlipara, G | 1 |
| Lillis, O | 2 |
| Dervan, JP | 1 |
| Cohn, PF | 1 |
| Karlsberg, RP | 1 |
| DeWood, MA | 1 |
| DeMaria, AN | 1 |
| Berk, MR | 1 |
| Lasher, KP | 1 |
| Levijoki, J | 1 |
| Pollesello, P | 1 |
| Kaheinen, P | 1 |
| Haikala, H | 1 |
| Sanada, S | 1 |
| Kitakaze, M | 1 |
| Papst, PJ | 1 |
| Asanuma, H | 1 |
| Node, K | 1 |
| Takashima, S | 1 |
| Asakura, M | 1 |
| Ogita, H | 1 |
| Liao, Y | 1 |
| Sakata, Y | 1 |
| Ogai, A | 1 |
| Fukushima, T | 1 |
| Yamada, J | 1 |
| Shinozaki, Y | 1 |
| Kuzuya, T | 1 |
| Mori, H | 1 |
| Terada, N | 1 |
| Hori, M | 1 |
| Pagani, ED | 1 |
| Buchholz, RA | 1 |
| Silver, PJ | 1 |
| Feneck, RO | 1 |
| Trolese-Mongheal, Y | 1 |
| Barthelemy, J | 1 |
| Paire, M | 1 |
| Duchene-Marullaz, P | 1 |
| Brown, EJ | 1 |
| Langenback, EG | 1 |
| Raeder, E | 1 |
| Halpern, J | 1 |
| Mannisi, JA | 1 |
| Schoemaker, RG | 2 |
| Smits, JF | 2 |
| Debets, JJ | 1 |
| Struyker-Boudier, HA | 1 |
| Lynch, JJ | 1 |
| Uprichard, AC | 1 |
| Frye, JW | 1 |
| Driscoll, EM | 1 |
| Kitzen, JM | 1 |
| Lucchesi, BR | 1 |
| DeFelice, A | 1 |
| Harris, A | 1 |
| Frering, R | 1 |
| Horan, P | 1 |
| Vleeming, W | 1 |
| van der Wouw, PA | 1 |
| van Rooij, HH | 1 |
| Wemer, J | 1 |
| Porsius, AJ | 1 |
| Sweet, CS | 2 |
| Ludden, CT | 1 |
| Stabilito, II | 2 |
| Emmert, SE | 2 |
| Heyse, JF | 1 |
| Drexler, H | 2 |
| Faude, F | 2 |
| Winterer, H | 1 |
| Wollschläger, H | 1 |
| Freudenberg, N | 1 |
| Just, H | 2 |
| Campbell, CA | 1 |
| Reddy, BR | 1 |
| Alker, KJ | 1 |
| Wynne, J | 1 |
| Kloner, RA | 1 |
| Höing, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Milrinone Versus Dobutamine in a Heterogeneous Population of Critically Ill Patients[NCT03207165] | Phase 4 | 192 participants (Actual) | Interventional | 2017-08-30 | Completed | ||
| Concomitant Milrinone and Esmolol Treatment in Patients With Acute Myocardial Infarction[NCT02098629] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2015-05-31 | Withdrawn (stopped due to Difficulty in enrollment) | ||
| Acute and Chronic Protective Effects of Peri-interventional Administration of Levosimendan in ST Elevation Myocardial Infarctions[NCT03022877] | 0 participants (Actual) | Interventional | 2017-06-30 | Withdrawn (stopped due to Rationale obsolete) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for milrinone and Cardiovascular Stroke
| Article | Year |
|---|---|
Milrinone for the Treatment of Acute Heart Failure After Acute Myocardial Infarction: A Systematic Review and Meta-Analysis.
Topics: Cardiotonic Agents; Heart Failure; Humans; Milrinone; Myocardial Infarction | 2015 |
Effect of milrinone on cardiac functions in patients undergoing coronary artery bypass graft: a meta-analysis of randomized clinical trials.
Topics: Cardiotonic Agents; Coronary Artery Bypass; Humans; Intensive Care Units; Length of Stay; Milrinone; | 2016 |
Role of nonglycosidic inotropic agents: indications, ethics, and limitations.
Topics: Adrenergic beta-Antagonists; Cardiac Glycosides; Cardiotonic Agents; Dobutamine; Ethics, Clinical; H | 2003 |
[Therapeutic options in cardiogenic shock].
Topics: Amrinone; Angioplasty, Balloon, Coronary; Assisted Circulation; Cardiotonic Agents; Coronary Artery | 1995 |
6 trials available for milrinone and Cardiovascular Stroke
| Article | Year |
|---|---|
Implications of Myocardial Infarction on Management and Outcome in Cardiogenic Shock.
Topics: Dobutamine; Heart Arrest; Humans; Milrinone; Myocardial Infarction; Percutaneous Coronary Interventi | 2021 |
No sex-based difference in cardiogenic shock: A post-hoc analysis of the DOREMI trial.
Topics: Dobutamine; Female; Heart Arrest; Humans; Male; Milrinone; Myocardial Infarction; Shock, Cardiogenic | 2022 |
Safety of combination therapy with milrinone and esmolol for heart protection during percutaneous coronary intervention in acute myocardial infarction.
Topics: Blood Pressure; Drug Therapy, Combination; Electrocardiography; Heart Rate; Humans; Infusions, Intra | 2014 |
Effect of milrinone on short-term outcome of patients with myocardial dysfunction undergoing coronary artery bypass graft: A randomized controlled trial.
Topics: Aged; Cardiotonic Agents; Coronary Artery Bypass; Creatine Kinase; Creatine Kinase, MB Form; Drug Ad | 2010 |
Comparative efficacy of short-term intravenous infusions of milrinone and dobutamine in acute congestive heart failure following acute myocardial infarction. Milrinone-Dobutamine Study Group.
Topics: Acute Disease; Aged; Cardiotonic Agents; Dobutamine; Echocardiography; Electrocardiography, Ambulato | 1996 |
Intravenous milrinone following cardiac surgery: II. Influence of baseline hemodynamics and patient factors on therapeutic response. The European Milrinone Multicentre Trial Group.
Topics: Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Blood Pressure; Cardiac Output; Cardiac Surgica | 1992 |
27 other studies available for milrinone and Cardiovascular Stroke
| Article | Year |
|---|---|
Combination of the Phosphodiesterase Inhibitors Sildenafil and Milrinone Induces Cardioprotection With Various Conditioning Strategies.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hemody | 2020 |
Milrinone-Induced Postconditioning Requires Activation of Mitochondrial Ca
Topics: Animals; Cardiotonic Agents; Dose-Response Relationship, Drug; Large-Conductance Calcium-Activated P | 2018 |
Differential effect of phosphodiesterase-3 inhibitors on sympathetic hyperinnervation in healed rat infarcts.
Topics: Animals; Cilostazol; Heart; Male; Milrinone; Myocardial Infarction; Phosphodiesterase 3 Inhibitors; | 2014 |
Sustained release of milrinone delivered via microparticles in a rodent model of myocardial infarction.
Topics: Animals; Blood Pressure; Cardiotonic Agents; Cell Adhesion Molecules; Chemistry, Pharmaceutical; Chr | 2014 |
Discussion.
Topics: Animals; Cardiotonic Agents; Female; Heart Failure; Milrinone; Myocardial Infarction | 2014 |
Methodological Perspectives from 'Milrinone for the Treatment of Acute Heart Failure After Acute Myocardial Infarction: A Systematic Review and Meta-analysis'.
Topics: Cardiotonic Agents; Heart Failure; Humans; Milrinone; Myocardial Infarction | 2015 |
Sympathomimetic inefficiency in restoring contractility in the acute or chronic beta-blocker-treated ischaemic heart: comparison with a new agent.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Cardiotonic Agents; Dobutamine; Dogs | 2008 |
Anti-ischemic effects of inotropic agents in experimental right ventricular infarction.
Topics: Animals; Blood Gas Analysis; Cardiotonic Agents; Dobutamine; Female; Heart Ventricles; Hemodynamics; | 2009 |
Hyperglycemia raises the threshold of levosimendan- but not milrinone-induced postconditioning in rat hearts.
Topics: Animals; Blood Glucose; Disease Models, Animal; Hemodynamics; Hydrazones; Hyperglycemia; Male; Milri | 2012 |
Milrinone combined with vasopressin improves cardiac index after cardiopulmonary resuscitation in a pig model of myocardial infarction.
Topics: Animals; Blood Pressure; Cardiopulmonary Resuscitation; Coronary Circulation; Disease Models, Animal | 2007 |
Effect of amrinone and milrinone on myocardial ischemia extent and infarct size in isolated rabbit hearts.
Topics: Amrinone; Animals; Cardiotonic Agents; Coronary Circulation; Fluorescence; Hemodynamics; Histocytoch | 1993 |
The effects of chronic oral milrinone therapy on early postinfarction left ventricular remodeling.
Topics: Administration, Oral; Analysis of Variance; Animals; Cardiotonic Agents; Disease Models, Animal; Dru | 1993 |
Improved survival with simendan after experimental myocardial infarction in rats.
Topics: Animals; Antihypertensive Agents; Cardiotonic Agents; Enalapril; Hydrazones; Male; Milrinone; Myocar | 2001 |
Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitors: the role of protein kinase A and p38 mitogen-activated protein kinase.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Blood Flow Velocity; Bucladesine; Calcium-Calmodulin-D | 2001 |
Cardiovascular cyclic nucleotide phosphodiesterases and their role in regulating cardiovascular function.
Topics: 1-Methyl-3-isobutylxanthine; Animals; Atrial Natriuretic Factor; Cyclic GMP; Heart Failure; Humans; | 1992 |
Arrhythmogenic potencies of amrinone and milrinone in unanesthetized dogs with myocardial infarct.
Topics: Amrinone; Analysis of Variance; Animals; Arrhythmias, Cardiac; Cardiotonic Agents; Dogs; Heart Rate; | 1992 |
Effects of milrinone on left ventricular remodeling after acute myocardial infarction.
Topics: Animals; Female; Heart; Heart Ventricles; Hemodynamics; Milrinone; Myocardial Infarction; Myocardium | 1991 |
Systolic time intervals as indicators for cardiac function in rat models for heart failure.
Topics: Age Factors; Animals; Blood Flow Velocity; Captopril; Cardiac Output; Cardiotonic Agents; Dobutamine | 1990 |
Beneficial hemodynamic effects of two weeks' milrinone treatment in conscious rats with heart failure.
Topics: Animals; Blood Pressure; Cardiac Output; Coronary Vessels; Heart Failure; Hemodynamics; Male; Milrin | 1990 |
Effects of the positive inotropic agents milrinone and pimobendan on the development of lethal ischemic arrhythmias in conscious dogs with recent myocardial infarction.
Topics: Animals; Arrhythmias, Cardiac; Cardiotonic Agents; Coronary Vessels; Dogs; Electric Stimulation; Ele | 1989 |
Beneficial hemodynamic effects of milrinone and enalapril in conscious rats with healed myocardial infarction.
Topics: Administration, Oral; Animals; Blood Pressure; Enalapril; Heart Rate; Hemodynamics; Male; Milrinone; | 1989 |
In vitro method for measurement of cardiac performance and responses to inotropic drugs after experimentally induced myocardial infarction in the rat.
Topics: Animals; Cardiotonic Agents; Coronary Circulation; Dobutamine; Heart; In Vitro Techniques; Male; Mil | 1989 |
Beneficial effects of milrinone and enalapril on long-term survival of rats with healed myocardial infarction.
Topics: Animals; Body Weight; Cardiomegaly; Cardiotonic Agents; Electrocardiography; Enalapril; Heart Failur | 1988 |
Acute and subacute hemodynamic effects of enalaprilat, milrinone and combination therapy in rats with chronic left ventricular dysfunction.
Topics: Animals; Antihypertensive Agents; Drug Therapy, Combination; Enalapril; Enalaprilat; Heart Failure; | 1987 |
[Central and regional vascular hemodynamics of milrinone in experimental heart failure: comparison with captopril and dobutamine].
Topics: Animals; Captopril; Dobutamine; Heart Failure; Hemodynamics; Male; Milrinone; Muscles; Myocardial In | 1987 |
Effect of milrinone on acute myocardial infarct size.
Topics: Animals; Cardiotonic Agents; Dogs; Hemodynamics; Milrinone; Myocardial Contraction; Myocardial Infar | 1987 |
Blood flow distribution within skeletal muscle during exercise in the presence of chronic heart failure: effect of milrinone.
Topics: Animals; Heart Failure; Hemodynamics; Male; Milrinone; Muscles; Myocardial Infarction; Physical Exer | 1987 |